Drug intelligence / Profile preview

cimetidine + tiotropium

Development stage
Phase 1
Lead developer
GSK
Modality
Small Molecules
Administration
Oral, Inhalation
01

Overview

Cimetidine + tiotropium is a combination of two pharmaceutical agents with distinct mechanisms of action and clinical indications. Cimetidine is a small molecule histamine H2 receptor antagonist that competitively inhibits histamine binding at the H2 receptor in gastric parietal cells, leading to reduced gastric acid secretion. It is primarily used for the management of gastroesophageal reflux disease (GERD), peptic ulcer disease, and related conditions[8]. Tiotropium is a long-acting antimuscarinic bronchodilator (anticholinergic) that acts as an antagonist at muscarinic acetylcholine receptors M1 to M5 in airway smooth muscle—most notably inhibiting the M3 receptor—to induce bronchodilation. Tiotropium is indicated for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and asthma[2][6]. There are no fixed-dose combination products containing both drugs; however, they may be co-administered in certain clinical scenarios. No clinically significant pharmacokinetic interaction has been observed between these agents[4][5].

Brand names
Good Sense Heartburn Relief
02

Targets

HRH2 (Histamine H2 Receptor)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)CHRM5 (M5)

Beyond the preview

Go deeper on cimetidine + tiotropium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cimetidine + tiotropium.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call